This is a case report of a 40-year-old woman who, after conservative breast cancer treatment, developed a HER2 positive solitary brain metastasis in the left temporal lobe, without extracranial disease. She underwent surgery resection followed by stereotactic radiotherapy and, because of early brain progression, she was submitted to the first line therapy with pertuzumab, trastuzumab and weekly paclitaxel. After six months of treatment, a brain magnetic resonance imaging revealed a complete disappearance of brain recurrence, which persisted for more than 24 months
Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients wh...
Breast cancer is the most common invasive cancer in women worldwide. It is the second leading cause ...
Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neop...
Patients with HER2-positive breast cancer and brain metastases have limited treatment options, and, ...
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpr...
Trastuzumab deruxtecán; Cáncer de mama metastásico; Metástasis cerebralesTrastuzumab deruxtecan; Met...
Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (H...
(1) Background: This study aims to assess the safety and efficacy of fractionated SRT (fSRT) and per...
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-...
Objective: Breast cancer is the second most common cause of brain metastasis (BM) among all of the s...
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer...
We aim to investigate the incidence, patterns and timing of brain metastases in advanced breast canc...
Background: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)...
The widespread use of trastuzumab in the past decade has led to a significant and measureable improv...
Breast tumors overexpressing Her2 (15% of breast cancers) are particularly at risk for central nervo...
Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients wh...
Breast cancer is the most common invasive cancer in women worldwide. It is the second leading cause ...
Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neop...
Patients with HER2-positive breast cancer and brain metastases have limited treatment options, and, ...
Trastuzumab is an effective treatment for patients with metastatic breast cancer (MBC) that overexpr...
Trastuzumab deruxtecán; Cáncer de mama metastásico; Metástasis cerebralesTrastuzumab deruxtecan; Met...
Since the introduction of targeted therapies, prognosis in human epidermal growth factor receptor (H...
(1) Background: This study aims to assess the safety and efficacy of fractionated SRT (fSRT) and per...
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-...
Objective: Breast cancer is the second most common cause of brain metastasis (BM) among all of the s...
The incidence of brain metastases (BMs) is apparently rising in patients with advanced breast cancer...
We aim to investigate the incidence, patterns and timing of brain metastases in advanced breast canc...
Background: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)...
The widespread use of trastuzumab in the past decade has led to a significant and measureable improv...
Breast tumors overexpressing Her2 (15% of breast cancers) are particularly at risk for central nervo...
Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients wh...
Breast cancer is the most common invasive cancer in women worldwide. It is the second leading cause ...
Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neop...